Investor Information

CannPal Finalises Key Terms with Leading Animal Health Partner

CannPal has successfully finalised key terms with a leading global animal health company to progress the development and commercialisation of CPAT-01, CannPal’s late-stage cannabinoid-based drug candidate for pain in dogs. The agreement is also expected to facilitate the U.S. launch of CannPal’s dermatology assets.

This development follows AusCann’s strategic decision in 2021 to divest its animal health assets, enabling CannPal to operate more efficiently as a private entity. The divestment allowed AusCann to conserve capital while retaining a 48% free-carried interest in CannPal, ensuring shareholders benefit from future potential revenues without additional financial obligations. Since the divestment, CannPal has been focused on advancing its core R&D initiatives and securing a strategic partner to support its commercial ambitions.

The finalisation of key terms with this global animal health leader represents a significant milestone in CannPal’s journey. The forthcoming agreement is expected to provide financial support for a Phase 2C dose-confirmation trial of CPAT-01, while securing pathways for the U.S. launch of its Dermatology assets. This partnership reaffirms the value of CannPal’s innovative R&D, positioning the company to unlock growth in the veterinary therapeutics market.

The final agreement is expected to be executed in the coming weeks. The Board of AusCann will continue to monitor progress and provide further updates once the agreement is completed.